Conceptus® Celebrates 10 Years of the Essure® Procedure With Symposium at European Society for Gynaecological Endoscopy (ESGE) 20th Annual Congress

News provided by

Conceptus, Inc.

20 Sep, 2011, 10:09 GMT

VERSAILLES, France, September 20, 2011 /PRNewswire/ --

22 Abstracts to be Presented on the Essure Procedure

Will Highlight Patient Experience and Use of Technology

Conceptus, Inc. (Nasdaq: CPTS), developer of the Essure® procedure, the most effective non-surgical permanent birth control method available, will host a symposium to celebrate the 10-year anniversary since the Essure procedure received the CE mark of approval for use in Europe.  The symposium will be held at the ESGE's 20th annual congress in London, England, on September 23, 2011 and will include the presentation of 22 ground-breaking abstracts (posters and free communications) demonstrating medical experience with the Essure procedure from contributors throughout Europe.  

The symposium will feature leading experts from the Netherlands, France, United Kingdom, and Spain who will review their experience with the Essure procedure during the past decade.  Topics will include Essure's long-term efficacy, patient acceptance, physician training and the latest confirmation techniques including the use of Transvaginal Ultrasound ("TVU") to confirm proper placement of Essure micro-inserts three months following the Essure procedure.  

M.P.H. Vleugels MD PhD FRCOG, department Obstetrics and Gynecology, Riverland Hospital Tiel, the Netherlands will present 10 years of data on the Essure procedure and participate in the roundtable discussion at the symposium.  

"We now have a decade of data on the Essure procedure and a body of evidence supporting its use as a positive alternative to laparoscopic sterilization surgery. The studies to be presented at ESGE examine the long-term use from the patient's perspective including patient satisfaction, as well as advances in confirmation testing technology and training methods.  Key findings indicate that the medical community has much to gain from continued adoption of the hysteroscopic sterilization procedure," said Dr. Vleugels.

The 22 new studies on the Essure procedure to be presented at ESGE Congress will offer valuable insight on patient experience and the use of technology for both physicians and medical centers.  Abstracts include:

  • P.10.20 Hysteroscopic Tubal Sterilization with Essure Device: What happens after? Velasco Sanchez, Arjona Berral, Povedano Canizares et al
  • P.10.3 A Review of Pain and Satisfaction with Outpatient Hysteroscopic Sterilisation.  Delgado Espeja, Solano Calvo, Heron Iglesias et al
  • FC.11.4 Face and Construct Validity of a Virtual Realist Simulator for Hysteroscopy Essure Sterilization, Janse J., Veersema S., Broekmans F. et al
  • P.06.6 3D Transabdominal Ultrasound.  A New Reliable Approach to Localise Essure Microinserts After Hysteroscopic Ambulatory Sterilization, Bader G., Bouhanna P. & Fauconnier A.
  • FC.09.8 Hysteroscopic Female Sterilisation in an Outpatient Setting, Fornelos G., Malafaia S., Campos R. et al
  • P.08.11 Introduction of New Technology: A Guideline for Surgeon and Medical Company, Vleugels M.

The Conceptus symposium will take place at the ESGE Annual Congress, London at 9:00am BST on September 23, 2011:

Essure, Standard of Care for Hysteroscopic Sterilization
Moderator: Pr. Mencaglia (IT)
Essure, 10 years of data: Dr. M. Vleugels (NL):
The Essure Confirmation Test Transvaginal Ultrasound, Flat plate X-Ray, HSG: Dr. S. Veersema (NL)

Round table discussion
Moderator: Dr. J. Frappell (UK)
Participants: Dr. M. Vleugels (NL) - Dr. S. Veersema (NL) - Dr. J. Clark (UK) - Pr. P. Lopes (FR) - Dr. J. E. Arjona Berral (ES)

About the Essure® Procedure

The Essure procedure, CE Mark approved since 2001 and FDA approved since 2002, is the first female permanent birth control method that can be performed in the comfort of a physician's office in less than 10 minutes (average hysteroscopic time) without hormones, cutting, burning or the risks associated with general anesthesia or tubal ligation. Soft, flexible inserts are placed in a woman's fallopian tubes through the cervix without incisions. Over the next three months, the body forms a natural barrier around and through the micro-inserts to prevent sperm from reaching the egg.  Three months after the Essure procedure, a doctor is able to perform an Essure Confirmation Test to confirm that the inserts are properly placed, allowing the patient to rely upon Essure for permanent birth control.

The Essure procedure is 99.95% effective based on one year of follow up with zero pregnancies reported in clinical trials, making it the most effective form of permanent birth control on the market. Essure has been proven and trusted by physicians since 2001, with approximately 550,000 women worldwide having undergone the Essure procedure.

About Conceptus, Inc.

Conceptus, Inc. is a leader in the design, development, and marketing of innovative solutions in women's healthcare. The Company manufactures and markets the Essure procedure.  The Essure procedure is available in the United States, Europe, Australia, New Zealand, Canada, Mexico, Central and South America and the Middle East.  The Company also promotes the GYNECARE THERMACHOICE® Uterine Balloon Therapy System by ETHICON™ Women's Health & Urology, a division of Ethicon, Inc., in U.S. OB/GYN physician offices.

Please visit http://www.essuremd.com or http://www.essure.com  for more information on the Essure procedure.

© 2011 Conceptus, Inc. - All rights reserved. Conceptus, Essure, Your Family is Complete, Your Choice is Clear are registered trademarks and service marks of Conceptus, Inc.  Essure FlexPay and Essurance Promise are trademarks of Conceptus, Inc.